Evidation partnered with Sanofi to understand potential differences in health impairment across comorbid respiratory conditions and demographic subgroups to identify previously unrecognized disease burden among those with Type 2 inflammation. Through our virtual cohort of nearly 4 million individuals, Evidation was able to connect with participants living with asthma, COPD, and/or nasal polyps to complete a digitally administered St. George’s Respiratory Questionnaire (SGRQ) which describes the symptom severity and health-related quality of life of respondents. Our research was presented at the 2020 ACAAI Annual Scientific Meeting showcasing preliminary findings on the disproportionate impact of respiratory conditions among females and those with COPD. In addition, participants with nasal polyps experienced greater functional burden compared to those without. Our findings may aid in the development of improved management strategies for these subgroups and guide future work to understand how an overlap of asthma and COPD may manifest in women.
Listen to the presentation here.
INTRODUCTION: Given that asthma and COPD are heterogeneous conditions, there is a need to understand potential differences in health impairment across comorbid conditions and demographic subgroups to identify previously unrecognized disease burden in Type 2 inflammation.
METHODS: Individuals from an online community self-reporting asthma, chronic obstructive pulmonary disease (COPD), and/or nasal polyps (NP) completed a digital version of a remotely administered St. George’s Respiratory Questionnaire (SGRQ), which assesses health impairment across three components: symptom frequency, physical activity, and psychosocial function. Higher total SGRQ scores (range = 0 to 100) indicated increased impairment. Between-group comparisons across comorbid combinations and demographics were conducted using one-way ANOVA and multivariable regression to adjust for covariates. The study was approved by Solutions IRB and determined to be exempt.
RESULTS: Survey response were analyzed for 1,888 participants across different respiratory conditions: asthma (n=1,055); COPD (n=318); asthma and COPD (n=244); asthma and NP (n=217); COPD and NP (n=19); and all three conditions (n=35). Groups with COPD had greater total SGRQ scores (means=44.0 to 56.7) compared to those without (asthma=28.5; asthma and NP=34.1). Higher total SGRQ scores were observed among females (β6.6, p<0.001) after adjustment for covariates, including COPD diagnosis. Notably, participants reporting COPD diagnosed before age 40 had higher total SGRQ scores compared to those diagnosed afterwards (β=6.0, p<0.001).
CONCLUSIONS: This novel pilot study of a remotely administered SGRQ identified disproportionate impact of respiratory conditions on females and those with COPD. This digitally-captured insight in a real-world setting may aid in development of improved management strategies for these subgroups.
Read the poster here.